What is Calixar?
Headquartered in Lyon, France, Calixar provides essential R&D services for the isolation and purification of native membrane proteins, including GPCRs, ion channels, and viral proteins. By maintaining the structural integrity and functionality of these challenging therapeutic targets, the company enables high-precision drug and biodrug discovery. Their methodology, which achieves 95% purity without denaturation, serves a diverse clientele of public and private research organizations. The company has demonstrated significant operational maturity, expanding its footprint from its French laboratories to include strategic business offices in Philadelphia and Tokyo, effectively bridging the gap between European innovation and international pharmaceutical markets.
How much funding has Calixar raised?
Calixar has raised a total of $1.1M across 1 funding round:
Unspecified
$1.1M
Unspecified (2015): $1.1M with participation from Savoie Angels, Veymont Participations, The Siparex Group, Grenoble Angels, and Health-Angels Rhu00f4ne-Alpes
Key Investors in Calixar
The Siparex Group
Siparex is an independent French private equity group dedicated to the development and transformation of businesses, ranging from startups to mid-sized enterprises.
Savoie Angels
Savoie Mont Blanc Angels helps small and medium businesses in the Alpine region get the money they need to grow through direct funding.
Veymont Participations
Veymont Participations is a consulting and business management services company based in Lyon, offering financial, legal, and administrative support.
What's next for Calixar?
The recent infusion of capital is expected to catalyze Calixar's next phase of growth, particularly as it scales its international presence. By leveraging its established offices in the United States and Japan, the company is poised to deepen its engagement with global pharmaceutical partners seeking advanced solutions for structure-based drug discovery and vaccine development. Future strategic efforts will likely focus on enhancing throughput for its isolation processes and expanding its portfolio of therapeutic targets, ensuring that Calixar remains at the forefront of the biotechnology sector as it transitions into a more robust, enterprise-level entity.
See full Calixar company page
